Items 1 ~ 10 of 2131, Page 1 of 213    Go to Headlines
  08/22/2019 MERCK
Merck Highlights New Data from Leading Lung Cancer Clinical Development Program at the IASLC 2019 World Conference on Lung Cancer
- Pooled Overall Survival (OS) Data from Three Trials with KEYTRUDA® (pembrolizumab) Plus Chemotherapy in Subgroup of Patients with Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Do Not Express PD-L1 / New KEYTRUDA Monotherapy Data in NSCLC Include Three-Year OS Data from Phase 3 KEYNOTE-024 and First-Time Data in Chinese Patients from Phase 3 KEYNOTE-042
  08/16/2019 Medtronic
Medtronic Evolut TAVR System Receives Expanded Indication to Treat Symptomatic Severe Aortic Stenosis Patients at Low Risk for Surgical Mortality
- Expanded TAVR Indication to Younger, More Active Patients Signals Groundbreaking Shift in the Future Treatment of Heart Valve Disease
  08/16/2019 Medtronic
Medtronic Approved to Start Pivotal Trial to Evaluate New Extended Wear Infusion Set
- Experimental Infusion Set Aims to Address Patient Burden with Comfort and Convenience Features for Insulin Pump Therapy
  08/14/2019 Abbott
Abbott and Intoximeters Partner to Keep Roads Safer by Bringing Together Industry-leading Technology for Drug and Alcohol Testing
- Agreement gives law enforcement access to the most advanced handheld tools to help detect drug and alcohol-impaired drivers / Collaboration is a major step in keeping roads safer as recreational marijuana legalization accelerates[1]
  08/14/2019 MERCK
LYNPARZA® (olaparib) Phase 3 PAOLA-1 Trial Met Primary Endpoint as First-Line Maintenance Treatment with Bevacizumab for Advanced Ovarian Cancer
- AstraZeneca and Merck’s LYNPARZA, When Added to Standard-of-Care Bevacizumab, Significantly Reduced the Risk of Disease Progression or Death in Women Who Responded to Platinum-Based Chemotherapy
  07/31/2019 MERCK
FDA Approves New Monotherapy Indication for Merck’s KEYTRUDA® (pembrolizumab)
- KEYTRUDA Now Approved for Recurrent Locally Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus in Patients Whose Tumors Express PD-L1 (CPS ≥10) With Disease Progression After One or More Prior Lines of Systemic Therapy
  07/30/2019 MERCK
Merck Announces Second-Quarter 2019 Financial Results
  07/29/2019 MERCK
Merck Receives Positive EU CHMP Opinion for ZERBAXA® 3g Dose (ceftolozane and tazobactam) for the Treatment of Adults with Hospital-Acquired Pneumonia (HAP), Including Ventilator-Associated Pneumonia (VAP)
  07/29/2019 MERCK
European Medicines Agency Adopts Positive Opinion for Merck’s KEYTRUDA® (pembrolizumab) in Combination with Inlyta® (axitinib) as First-Line Treatment for Advanced Renal Cell Carcinoma
- Opinion Granted Based on Significant Overall Survival Benefit for KEYTRUDA in Combination with Axitinib Compared to Sunitinib in Phase 3 KEYNOTE-426 Trial
  07/29/2019 MERCK
Merck’s KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy Met Primary Endpoint of Pathological Complete Response (pCR) in Pivotal Phase 3 KEYNOTE-522 Trial in Patients with Triple-Negative Breast Cancer (TNBC)
- KEYTRUDA is the First Anti-PD-1 Therapy to Demonstrate a Statistically Significant Improvement in pCR Rates as Neoadjuvant Therapy for TNBC Regardless of PD-L1 Status / Data to be Presented at an Upcoming Medical Congress and Discussed with Regulatory Authorities

<<  <  [1[2]  [3]  [4]  [5]  [6]  [7]  [8]  [9]  [10]  >  >>